New data on antihypertensive drugs and risk of cancer: should we worry?

New data on antihypertensive drugs and risk of cancer: should we worry?

Bibliographic Details
Main Authors:	Michel Burnier, Krzysztof Narkiewicz, Sverre E. Kjeldsen, Suzanne Oparil
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2019-01-01
Series:	Blood Pressure
Online Access:	http://dx.doi.org/10.1080/08037051.2019.1568182

Similar Items

The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug
by: Sverre E. Kjeldsen, et al.
Published: (2021-11-01)

Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers
by: Sverre E. Kjeldsen, et al.
Published: (2021-01-01)

Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project
by: Reinhold Kreutz, et al.
Published: (2020-05-01)

The International Society of Hypertension Guidelines 2020 – a new drug treatment recommendation in the wrong direction?
by: Sverre E. Kjeldsen, et al.
Published: (2020-09-01)

Cuff-less measurements of blood pressure: are we ready for a change?
by: Michel Burnier, et al.
Published: (2021-07-01)

Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?
by: Sverre E. Kjeldsen, et al.
Published: (2019-03-01)

Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines?
by: Sverre E. Kjeldsen, et al.
Published: (2020-11-01)

Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited
by: Sverre E. Kjeldsen, et al.
Published: (2019-05-01)

How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers
by: Michel Burnier, et al.
Published: (2020-03-01)

The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke
by: Sverre E. Kjeldsen, et al.
Published: (2017-05-01)

Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes – from single pill combinations to monitoring of a nationwide health insurance database
by: Sverre E. Kjeldsen, et al.
Published: (2021-05-01)

Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials
by: Sverre E. Kjeldsen, et al.
Published: (2017-09-01)

Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial?
by: Sverre E. Kjeldsen, et al.
Published: (2020-07-01)

The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension
by: Sverre E. Kjeldsen, et al.
Published: (2020-01-01)

New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?
by: Michel Burnier, et al.
Published: (2018-03-01)

2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension
by: Sverre E. Kjeldsen, et al.
Published: (2018-11-01)

Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection
by: Krzysztof Narkiewicz, et al.
Published: (2021-09-01)

The PARAGON Heart Failure trial – ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction
by: Sverre E. Kjeldsen, et al.
Published: (2019-07-01)

Renal denervation in hypertension: is it the end or the beginning of a SPYRAL?
by: Michel Burnier, et al.
Published: (2017-11-01)

The PARAGON-Heart failure trial – another disappointment for heart failure patients with hypertension and preserved ejection fraction
by: Sverre E. Kjeldsen, et al.
Published: (2019-09-01)

Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study
by: Sverre E. Kjeldsen, et al.
Published: (2018-09-01)

The INTERSALT Study and the complex relationship between salt intake and blood pressure
by: Sverre E. Kjeldsen, et al.
Published: (2017-03-01)

In memoriam: Alberto Zanchetti
by: Sverre E. Kjeldsen, et al.
Published: (2018-05-01)

Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes
by: Sverre E. Kjeldsen, et al.
Published: (2019-11-01)

Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure
by: Sverre E. Kjeldsen, et al.
Published: (2018-07-01)

Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions
by: Krzysztof Narkiewicz, et al.
Published: (2018-01-01)

The Global Burden of Disease Study 2015 and Blood Pressure
by: Sverre E. Kjeldsen, et al.
Published: (2017-01-01)

Blood pressure target in patients with hypertension and type-2 diabetes older than 65 years. Is <130/80 mmHg the right target or an excessive objective preventing from achieving the clinical goals we are aiming at?
by: Michel Burnier, et al.
Published: (2021-03-01)

In memoriam: Peter Sleight 1929–2020
by: Reinhold Kreutz, et al.
Published: (2020-11-01)

In memoriam: Jiří Widimský Sr. 1925–2020
by: Reinhold Kreutz, et al.
Published: (2021-03-01)

Prevention of heart failure mortality and hospitalizations in SPRINT, EMPA-REG, ALLHAT and HYVET: are diuretics the clue?
by: Michel Burnier, et al.
Published: (2017-07-01)

Women’s health, cardiovascular risk and hypertension: the perspective still needs to improve
by: Michel Burnier, et al.
Published: (2023-12-01)

Should we worry about 'flurona' ?
by: Musa, Husna
Published: (2023)

Antisemitism in Europe: should we worry?
by: Hedges, Paul
Published: (2023)

Zika virus in the testes: should we be worried?
by: Gary Wong, et al.
Published: (2017-01-01)

Forex market rigging : should we not worry?
by: J. Soedradjad Djiwandono
Published: (2015)

Why we should be worried about the future of nutrition
by: Sushmitha Mahantshetti, et al.
Published: (2023-11-01)

Type 2 diabetes in the young: Why we should worry
by: Thanabalasingham, G, et al.
Published: (2014)

Isolated disproportionately raised alkaline phosphatase: should we worry?
by: Lee, Yee Lin, et al.
Published: (2020)

Latin America: Should We Be Worried about Zika Virus
by: Joselyn Ye, et al.
Published: (2016-12-01)